Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma.

被引：1

作者：

Slingluff, Craig L.

Blumenstein, Brent A.

Lewis, Karl D.

Andtbacka, Robert Hans Ingemar

Hyngstrom, John Robert

Milhem, Mohammed M.

Markovic, Svetomir

Hamid, Omid

Hernandez-Aya, Leonel Fernando

Bowles, Tawnya Lynn

Philips, Prejesh

Jang, Sekwon

Lutzky, Jose

Bar, Anna

Beitsch, Peter D.

机构：

[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

[2] Trial Architecture Consulting, Washington, DC USA

[3] Univ Colorado Denver, Sch Med, Aurora, CO USA

[4] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[5] Univ Utah, Salt Lake City, UT USA

[6] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

[7] Mayo Clin, Rochester, MN USA

[8] Angeles Clin & Res Inst, Los Angeles, CA USA

[9] Univ Michigain Hlth Syst, Ann Arbor, MI USA

[10] Intermt Med Ctr, Murray, UT USA

[11] Univ Louisville, Louisville, KY 40292 USA

[12] Inova Schar Canc Inst, Fairfax, VA USA

[13] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA

[14] OHSU Knight Canc Inst, Portland, OR USA

[15] Dallas Surg Grp, Dallas, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10017

引用

页数：2

共 50 条

[31] Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.
Grossmann, Kenneth F.
Othus, Megan
Patel, Sapna Pradyuman
Tarhini, Ahmad A.
Sondak, Vernon K.
Petrella, Teresa M.
Truong, Thach-Giao
Khushalani, Nikhil I.
Cohen, Justine Vanessa
Buchbinder, Elizabeth Iannotti
Kendra, Kari Lynn
Funchain, Pauline
Lewis, Karl D.
Chmielowski, Bartosz
Li, Hongli
Moon, James
Gunturu, Krishna Soujanya
Eroglu, Zeynep
Kirkwood, John M.
Ribas, Antoni
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European cooperative adjuvant melanoma treatment study group
Richtig, E
Soyer, HP
Posch, M
Mossbacher, U
Bauer, P
Teban, L
Svolba, G
Wolf, IH
Fritsch, P
Zelger, B
Volc-Platzer, B
Gebhart, W
Mischer, P
Steiner, A
Pachinger, W
Hintner, H
Gschnait, F
Rappersberger, K
Pilarski, P
Pehamberger, H
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) : 8655 - 8663
[33] Peri-operative treatment with RBPI21 in the prevention of complications after major liver resection:: A randomized, double-blind, placebo-controlled, multicenter trial.
Wiezer, MJ
Meijer, C
Gouma, DJ
Tilanus, HW
Van de Velde, CJ
Wiggers, T
Zoetmulder, FA
Thijs, LG
Vanhove, GF
Bauer, RJ
Van Leeuwen, PA
HEPATOLOGY, 1999, 30 (04) : 213A - 213A
[34] Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, M. A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. Puig
Ascierto, P. A.
Lorigan, P.
Grebennik, D.
Krepler, C.
Marreaud, S. I.
Suciu, S.
Robert, C.
ANNALS OF ONCOLOGY, 2024, 35 : S725 - S726
[35] Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients - Randomized, double-blind, placebo-controlled trial
Brown, VL
Atkins, CL
Ghali, L
Cerio, R
Harwood, CA
Proby, CM
ARCHIVES OF DERMATOLOGY, 2005, 141 (08) : 985 - 993
[36] Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial
Natsume, Osamu
Kabashima, Shigenori
Nakazato, Junko
Yamamoto-Hanada, Kiwako
Narita, Masami
Kondo, Mai
Saito, Mayako
Kishino, Ai
Takimoto, Tetsuya
Inoue, Eisuke
Tang, Julian
Kido, Hiroshi
Wong, Gary W. K.
Matsumoto, Kenji
Saito, Hirohisa
Ohya, Yukihiro
LANCET, 2017, 389 (10066) : 276 - 286
[37] A PHASE-II MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF 3 DOSAGES OF AN IMMUNOMODULATOR (PGG-GLUCAN) IN HIGH-RISK SURGICAL PATIENTS
BABINEAU, TJ
HACKFORD, A
KENLER, A
BISTRIAN, B
FORSE, RA
FAIRCHILD, PG
HEARD, S
KEROACK, M
CAUSHAJ, P
BENOTTI, P
ARCHIVES OF SURGERY, 1994, 129 (11) : 1204 - 1210
[38] High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial)
De Smedt, Julie
Van Kelst, Sofie
Janssen, Laudine
Marasigan, Vivien
Boecxstaens, Veerle
Bogaerts, Kris
Belmans, Ann
Vanderschueren, Dirk
Vandenberghe, Katleen
Bechter, Oliver
Aura, Claudia
Lambrechts, Diether
Strobbe, Tinne
Emri, Gabriella
Nikkels, Arjen
Garmyn, Marjan
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 (06) : 886 - 896
[39] Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
Diener, HC
Bogousslavsky, J
Brass, LM
Cimminiello, C
Csiba, L
Kaste, M
Leys, D
Matias-Guiv, J
Rupprecht, HJ
LANCET, 2004, 364 (9431) : 331 - 337
[40] Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial - The SARAH Trial
Bonatto, Marcely
Ferreira, Silvia
Avila, Monica
Lechinewski, Luka
Torres, Rafael
Costa, Amanda
Coiradas, Andressa
Costa, Nadya
Contin, Lais
Maiolino, Julyana Zaninelli
Mosko, Larissa Arlete
Mialski, Talita
Ota, Tammy
Moura, Lidia
Cauduro, Sanderson
Bocchi, Edimar
CIRCULATION, 2024, 150 (25) : E724 - E725

← 1 2 3 4 5 →